Abstract
In this chapter, we discuss de-esclation of treatment for patients with HPV-positive disease. We discuss the rationale for de-escalation (why de-escalate?), patient selection criteria (who to de-esclate?) and what the treatment options for de-esclation are and the studies that are currently being run in those areas (how to de-escalate?). We stress the importance of clinicians NOT changing the management of oropharyngeal cancer patients outside clinical trials, and encourage them to recruit to the ongoing studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35
Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578
Brotherston DC, Poon I, Le T et al (2013) Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck 35(2):151–159
Cmelak A, Li S, Marur S, et al (2014) E1308: reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). In: ASCO annual meeting proceedings 2014, p LBA6006
Haughey BH, Sinha P (2012) Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer. Laryngoscope 122(Suppl 2):S13–S33
Huang SH, Xu W, Waldron J et al (2015) Refining American joint committee on cancer/union for international cancer control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol 33(8):836–845
Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589
O’Sullivan B, Huang SH, Siu LL et al (2013) Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31(5):543–550
Sinha P, Lewis JS, Piccirillo JF, Kallogjeri D, Haughey BH (2012) Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 118(14):3519–3530
Trotti A, Pajak TF, Gwede CK et al (2007) TAME: development of a new method for summarising adverse events of cancer treatment by the radiation therapy oncology group. Lancet Oncol 8(7):613–624
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mehanna, H. (2017). Update on De-intensification and Intensification Studies in HPV. In: Golusiński, W., Leemans, C., Dietz, A. (eds) HPV Infection in Head and Neck Cancer. Recent Results in Cancer Research, vol 206. Springer, Cham. https://doi.org/10.1007/978-3-319-43580-0_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-43580-0_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43578-7
Online ISBN: 978-3-319-43580-0
eBook Packages: MedicineMedicine (R0)